← Home
The Indicator from Planet Money · May 19, 2026 · 10m

Why GLP-1s aren't lowering employers' costs

Show Notes

Only about 20% of employer health plans cover GLP-1 weight-loss drugs like Wegovy or Zepbound, despite their popularity. The episode examines whether covering these expensive drugs actually saves employers money by reducing other healthcare costs tied to obesity. There’s still no clear answer, leaving companies to make a bet with their healthcare budgets.

This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.

Highlights

•
GLP-1 Cost-Savings Unclear for Employers
The episode explores whether employer spending on GLP-1 drugs for weight loss is offset by lower medical costs from obesity-related conditions.
ClaudeChatGPTGemini
•
Low Employer Coverage for Weight-Loss Drugs
Only roughly 20% of employer health plans cover GLP-1s for weight loss.
ClaudeChatGPTGemini

Editorial

•
The Employer's GLP-1 Gamble
Employers must decide whether to cover expensive GLP-1 drugs without clear evidence on long-term financial returns.
ClaudeChatGPTGemini
Was this useful?